Source: Sports Physio
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Healthia (HLA) has entered into a binding agreement to purchase Sandringham Sports Physio in Victoria
  • The company will pay just over $1.5 million for the physio in a cash and share deal
  • Healthia says the deal is expected to contribute around $1.7 million to its revenue
  • Additionally, the company has also completed its buyout of The Physio Clinic, which includes three clinics in South Australia
  • On the market, Healthia is up 1.57 per cent and is trading at $1.94 million

Healthia (HLA) has entered into a binding agreement to purchase Sandringham Sports Physio in Victoria.

The company will pay just over $1.5 million for the physio in a cash and share deal.

Sandringham is a physiotherapy clinic located in Victoria and was established over 30 years ago.

The clinic provides physiotherapy and other allied health services, such as myotherapy, podiatry, pilates and dietetics to the Sandringham and Bayside community.

Healthia says the deal is expected to contribute around $1.7 million to its revenue.

The Physio Clinic

Last December, the company entered a binding agreement to purchase The Physio Clinic for around $1.4 million.

The Physio Clinic included three physiotherapy clinics in South Australia.

Today, the company has completed that purchase. The deal is expected to bring the company $2.5 million in revenue.

On the market, Healthia is up 1.57 per cent and is trading at $1.94 million at 1:24 pm AEDT.

HLA by the numbers
More From The Market Online

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…

Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported…

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics takes its latest drug for Polycystic Kidney Disease, characterized by the formation of cysts…